Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB grew its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 23.6% in the 1st quarter, Holdings Channel reports. The institutional investor owned 42,981 shares of the company’s stock after buying an additional 8,200 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Tarsus Pharmaceuticals were worth $2,208,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Crowley Wealth Management Inc. acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at approximately $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at approximately $44,000. Quarry LP acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at approximately $166,000. HighTower Advisors LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at approximately $207,000. Finally, Summit Investment Advisors Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company’s stock valued at $213,000 after buying an additional 244 shares during the period. 90.01% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 3,341 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $154,654.89. Following the sale, the general counsel now owns 58,057 shares in the company, valued at approximately $2,687,458.53. This represents a 5.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dianne C. Whitfield sold 2,137 shares of the stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $107,085.07. Following the sale, the insider now owns 46,355 shares in the company, valued at approximately $2,322,849.05. This trade represents a 4.41% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,542 shares of company stock worth $1,581,173. 8.97% of the stock is owned by insiders.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS opened at $43.92 on Friday. The business’s fifty day moving average price is $46.22 and its two-hundred day moving average price is $48.85. The stock has a market cap of $1.85 billion, a PE ratio of -11.53 and a beta of 0.83. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.05. The firm had revenue of $78.34 million for the quarter, compared to analysts’ expectations of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. On average, analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Oppenheimer assumed coverage on Tarsus Pharmaceuticals in a research note on Monday, June 2nd. They issued an “outperform” rating and a $75.00 price objective for the company. Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Jefferies Financial Group raised their price objective on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Guggenheim raised their price objective on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. Finally, HC Wainwright raised Tarsus Pharmaceuticals to a “buy” rating and set a $72.00 price objective for the company in a research note on Tuesday, May 27th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $66.67.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.